Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study.

Osteoporos Int · 2014 · PMC4134483 · PMID 24899103

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

In all subgroups, VAS scores demonstrated a decreasing trend after switching, with the decreases in the subgroups of patients who switched from alendronate and daily dose of minodronate statistically significant at 1 month after treatment and subsequent time points ( p < 0.05).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.